Davis Polk advised the sales agents, RBC Capital Markets, LLC and Evercore Group L.L.C., on the transaction. Emergent BioSolutions Inc., an American multinational specialty biopharmaceutical company headquartered in...
Emergent BioSolutions’ $150 Million At-the-market Offering
Forbion European Acquisition’s $135 Million Combination with enGene
Davis Polk advised Forbion European Acquisition Corp. (FEAC), a SPAC, on the acquisition. Stikeman Elliott LLP served as Canadian legal counsel, Maples Group served as legal...
Bloom Energy’s $632.5 Million Green Convertible Notes and Capped Call Transactions
Davis Polk advised the representatives of the initial purchasers in the offering and also advised the counterparties on capped call transactions. Bloom Energy Corporation (NYSE: BE)...
Schlumberger’s $1 Billion Senior Notes Offering
Gibson Dunn, Loyens & Loeff and STvB Advocaten advised Schlumberger, while Davis Polk advised the representatives of the underwriters. Schlumberger Investment S.A. announced an SEC-registered debt...
Integral Ad Science’s $165.6 Million Secondary Offering
Kirkland & Ellis advised Integral Ad Science and entities affiliated with Vista Equity Partners, while Davis Polk advised the representatives of the underwriters. Integral Ad Science...
ACELYRIN’s $621 Million Initial Public Offering
Cooley advised ACELYRIN, and Davis Polk advised the joint book-running managers. ACELYRIN, INC. announced its upsized initial public offering of 34,500,000 shares of common stock at...
Cellular Biomedicine Group’s CAR-T License Agreement With Janssen
Janssen advised Cellular Biomedicine Group CAR-T on the transaction. Cellular Biomedicine Group signed an exclusive collaboration and license agreement with Janssen Biotech, Inc., pursuant to which Janssen...
Gamida Cell’s $23 Million Follow-On Offering
Meitar and Cooley advised Gamida Cell on the offering, and Davis Polk advised the underwriter. Gamida Cell Ltd. announced the $23 million SEC-registered follow-on offering of...
AVITA Medical’s At-The-Market Offering
K&L Gates advised AVITA, and Davis Polk advised the sales agent for the offering. AVITA Medical, Inc. announced the establishment of an SEC-registered at-the-market program of...
InflaRx’s $40 Million Follow-On Offering
NautaDutilh and Kirkland & Ellis advised InflaRx on the offering, and Davis Polk advised the representative of the underwriters involved. InflaRx N.V. announced a public offering...
Medtronic Global Holdings’ $2 Billion Notes Offering
Wilmer Cutler, DLA Piper and A&L Goodbody advised Medtronic, while Davis Polk advised the representatives of the several underwriters. Medtronic Global Holdings S.C.A. issued $1 billion...
Intercept Pharmaceuticals’ $100 Million Common Stock Offering
DLA Piper advised Intercept Pharmaceuticals on the offering, and Davis Polk advised the sales agent involved. Intercept Pharmaceuticals, Inc. announced the SEC-registered at-the-market offering of its...